This cell line was screened using the siRNA library targeting 1310 genes in combination with vehicle or SAIT301 at IC20

This cell line was screened using the siRNA library targeting 1310 genes in combination with vehicle or SAIT301 at IC20. of SAIT301 in SAIT301-resistant cells and enhanced the efficacy in SAIT301-sensitive cells. In addition to FGFR3, integrin 3 is usually another potential target for combination treatment with SAIT301. Suppression of integrin 3 decreased AKT phosphorylation in SAIT301-resistant cells and restores SAIT301 responsiveness in HCC1954 cells, which are resistant to SAIT301. Gene expression analysis using CCLE database shows malignancy cells with high levels of FGFR and integrin 3 are resistant to crizotinib treatment, suggesting FGFR and integrin 3 could be Exatecan mesylate used as predictive markers for Met targeted therapy and provide a potential therapeutic option to overcome acquired and innate resistance for the Met targeting drugs. mutant NSCLCs19. In turn, the activation of the HER family was shown to be responsible for the resistance of PHA665752, a Met specific inhibitor, in Met-addicted gastric cancer cells20,21. It was also reported that resistance to Met Exatecan mesylate targeting inhibitors can occur through point mutations, especially at Y123022, gene amplification followed by over-expression in Met-addicted gastric and lung cancer cells23, and over-expression of constitutively active SND1-BRAF fusion protein24. In NSCLC, the mechanism of acquired resistance to EGFR/Met tyrosine kinase inhibitor was attributed to the activation of mammalian target of rapamycin (mTOR) and the Wnt signaling pathway25. However, the underlying mechanism of acquired or inherent resistance to Met targeted antibodies has not been fully elucidated26C28. Although the relationship between Met and other RTKs in the survival of Met drug resistant cancer cells remains uncertain, it Exatecan mesylate has been shown that Met inhibitor-driven resistance could be rescued by inactivation of fibroblast growth Exatecan mesylate factor receptor (FGFR) by small molecules29,30. Recently, many approaches have focused on discovering biomarkers for patient selection and exploring novel combination therapies31. To systematically identify targets whose inhibition would increase the response of cancer cells to Met inhibitors, we performed medium-throughput siRNA library synthetic lethal screening targeting genes associated with systems biology-derived EGFR and Met signaling pathways32. Here, we show that FGFR could have a role Rabbit Polyclonal to PSMD2 as an alternative driver kinase for Met because dependence on either FGFR or Met can be compensated by activation of the other kinase. Therefore, simultaneous inhibition of FGFR and Met or intervention at a common downstream effector such as AKT is required for effective Met targeted anti-cancer therapeutics. Previous studies have shown that integrin 1 mediates EGFR drug resistance and its association with the Met signaling pathway in NSCLCs33. Integrin subunits are adhesion molecules involved in cell survival and cancer resistance to chemotherapy in breast cancers34,35. Here, we identify significant crosstalk between integrin 3 and Met in HCC1954 breast malignancy cells and investigate the mechanism of Met drug resistance related to integrin signaling. We also demonstrate that perturbation of integrin 3 and FGFR signaling significantly inhibits proliferation of SAIT301-resistant MKN45 cells. These data provide a strong rationale for the use of integrin 3 and FGFR inhibitors in Met-amplified tumors that have become resistant to selective Met inhibition, or to combined therapy to prevent these resistance mechanisms. Our findings demonstrate a specific crosstalk of integrin, FGFR and Met pathways and suggest the partial overlap of downstream signaling and common cellular effects of each pathway. Results Synthetic lethal screening to identify sensitizers of cellular response to a Met inhibitor In order to identify molecular determinants that modulate cellular responses to Met-targeted therapies we developed a siRNA library and performed synthetic lethal screening using a Met-specific monoclonal antibody, SAIT3017,36. Previously we reported that SAIT301 promotes Met degradation via a Exatecan mesylate LRIG1-mediated pathway. SAIT301 treatment promoted the binding of Met with LRIG1, bypassing the Cbl-mediated Met degradation pathway which requires Met activation. This unique.